Invalidity dossier

US 10865400

PH20 polypeptide variants, formulations and uses thereof

Current assignee: Merck Sharp & Dohme LLC

Added 5/12/2026, 11:37:41 PM

Active provider: Google · gemini-2.5-flash

Auto-generating section 1 of 2: Extensions…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

⚖️ Active PTAB challenge: 1 pending proceeding against this patent

1 active — Inter Partes Review, Post-Grant Review, or Covered Business Method proceedings at the USPTO Patent Trial and Appeal Board.

See proceedings →

Got a demand letter citing US 10865400?

Paste the full letter into the analyzer. We extract every asserted patent (this one and any others), characterize the asserter, flag validity vulnerabilities, and draft a sample response letter your attorney can adapt.

Analyze a letter →

Generic sample response letter (PDF)

Generates a draft reply letter to a generic infringement claim citing this patent, using the analysis in this dossier. For a response tailored to a specific letter you received, use the demand letter analyzer instead. Sample only — not legal advice. Do not send without review by a licensed patent attorney.

Watchlist

Get alerted when this patent moves.

Email-only, free, anonymous. We'll notify you when US 10865400 gets a new lawsuit, a new PTAB proceeding, or a new dossier section. One-click unsubscribe from any alert.

Patent summary

Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.

✓ Generated

US Patent 10865400, titled "PH20 polypeptide variants, formulations and uses thereof," was filed on August 2, 2016, and issued on December 15, 2020. The current assignee is Halozyme Inc and Halozyme Therapeutics Inc. The inventors are Ge Wei, H. Michael Shepard, Qiping Zhao, and Robert James Connor.

Abstract:
The patent describes modified PH20 hyaluronidase polypeptides, including variants that exhibit increased stability and/or increased activity. It also covers compositions, formulations, and uses of these modified polypeptides.

Independent Claims Overview:
Due to the limitations of the provided text, the specific wording of the independent claims for US10865400B2 is not available. Therefore, a plain-language overview of each independent claim cannot be provided with certainty.

Litigation Status:
The patent family is involved in ongoing litigation. A US case was filed in the New Jersey District Court (Case: 2:25-cv-03179). Additionally, there is a pending PTAB (Patent Trial and Appeal Board) case, IPR2026-00312, filed in 2026. This indicates ongoing challenges to the patent's validity. A search for direct CAFC 2026 dockets specifically mentioning US10865400 did not yield immediate results.

Generated 5/29/2026, 5:54:47 PM